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Summary
Background.— While there are convergent data suggesting that overall cardiovascular mortality
is increased in patients with rheumatoid arthritis, the relative contributions of myocardial
infarction and stroke remain unclear.
Aims.— We sought to clarify this issue by conducting a meta-analysis of cohort studies on
myocardial infarction and stroke in patients with rheumatoid arthritis.
Methods.— A MEDLINE search from January 1960 to September 2009 and abstracts from inter-
national conferences from 2007 to 2009 were searched for relevant literature. All cohort
studies reporting on standardized mortality ratio or incidence rate ratio of myocardial or
stroke associated with rheumatoid arthritis, with available crude numbers, were included. STATA
meta-analysis software was used to calculate pooled risk estimates.
Abbreviations: CI, conﬁdence interval; CV, cardiovascular; IRR, incidence rate ratio; MI, myocardial infarction; RA, rheumatoid
arthritis; SMR, standardized mortality ratio.
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Accident vasculaire
cérébral ;
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Conclusion.— Nos résultats montrent qu’il existe un sur-risque d’infarctus du myocarde et
d’accident vasculaire cérébral au cours de la polyarthrite rhumatoïde ; tous deux contribuent
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ackground
heumatoid arthritis (RA) is a chronic systemic inﬂamma-
ory disease, of unknown origin, that affects 0.5—1% of the
dult population [1,2]. Over the past decade, several studies
ave shown that RA is associated with an increased cardio-
ascular (CV) mortality [3—6]. This has been conﬁrmed by
ome meta-analyses that documented a 50—60% increase in
V mortality in RA patients [7—9]. However, although some
tudies speciﬁcally reported the risk of myocardial infarc-
ion (MI), there are fewer data on stroke. Additionally, it has
een suggested that the impact of RA on the risk of stroke
ay be weaker [10]. Two meta-analyses investigated con-
omitantly CV mortality, MI and stroke, but these studies
ad some limitations [7,8]. One pooled standardized mor-
ality ratio (SMR) and incidence rate ratio (IRR), and was
ot exhaustive [7]. The other meta-analysis did not include
tudies performed after 2005, a period of major advances
n disease-modifying antirheumatic drugs [8]. Therefore,
he relative impact of RA on MI and stroke remain unclear.
o clarify this issue, we performed a systematic review of
ublished studies to assess the risk of MI and stroke in RA
atients.
I
E
durs de la polyarthrite rhumatoïde.
s droits réservés.
ethods
earch methods for identiﬁcation of studies
e sought studies published between January 1960 and
eptember 2009, without restriction in settings or lan-
uage. Electronic searches were performed using MEDLINE,
ith both keywords and free text words ‘‘rheumatoid
rthritis’’ and (‘‘mortality’’ or ‘‘myocardial infarction’’ or
‘cardiovascular disease’’ or ‘‘stroke’’ or ‘‘cerebrovascular
ccident’’ or ‘‘coronary artery disease’’). We reviewed the
eference lists of all included studies, any relevant guide-
ines, general reviews, and commentaries pertaining to the
anagement of patients with rheumatoid arthritis. To iden-
ify recent studies not yet published as full papers, we also
earched books of abstracts from 2007 to 2009 conferences
European League against Rheumatism [EULAR] and Ameri-
an College of Rheumatology [ACR]).C. Meune et al.
Results.— Seventeen papers fulﬁlled the inclusion criteria, corresponding to a total of
124,894 patients. Ten studies reported on standardized mortality ratio for fatal myocar-
dial infarction, which ranged from 0.99 to 3.82. The overall pooled estimate was 1.77
(95% conﬁdence interval [CI] 1.65—1.89). Incidence rate ratio for myocardial infarction was
reported in ﬁve studies; the pooled estimate was 2.10 (95% CI 1.52—2.89). Nine studies reported
on fatal stroke, with standardized mortality ratio ranging from 1.08 to 2.00; the pooled esti-
mate was 1.46 (95%CI 1.31—1.63). The pooled incidence rate ratio for stroke (three studies)
was 1.91 (95%CI 1.73—2.12).
Conclusion.— Our results show that risks of myocardial infarction and stroke are increased
in patients with rheumatoid arthritis. In addition, both account for the observed increased
mortality in individuals with rheumatoid arthritis.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Introduction.— La mortalité cardiaque globale est augmentée au cours de la polyarthrite rhu-
matoïde, mais le niveau de risque de survenue d’un infarctus du myocarde et d’un accident
vasculaire cérébral demeurent incertains.
Objectif.— Préciser ce niveau de risque à l’aide d’une méta-analyse.
Méthodes.— La recherche a été effectuée sur Medline, de janvier 1960 à septembre 2009 et à
partir des abstracts des conférences internationales de 2007 à 2009. Les études de cohorte
rapportant les risques de mortalité (SMR) et les taux d’incidence (IRR) d’infarctus du
myocarde ou d’accident vasculaire cérébral au cours de la polyarthrite rhumatoïde ont été
inclues.
Résultats.— Dix-sept articles et/ou abstracts ont été retenus, ce qui correspond à une popu-
lation totale de 124 894 patients. Dix études rapportent le SMR pour l’infarctus du myocarde
fatal; il varie entre 0,99 et 3,82 selon les études. Le SMR global calculé est de 1,77 (IC 95% :
1,65—1,89). Le risque de survenue d’infarctus du myocarde total a été rapporté dans cinq
études ; le risque global calculé est de 2,10 (IC 95% : 1,52—2,89). Neuf études ont rapporté le
risque d’accident vasculaire cérébral fatal avec des SMR compris entre 1,08 et 2,00 ; le SMR
global est de 1,46 (IC 95% : 1,31—1,63). Le risque d’accident vasculaire cérébral total est de
1,91 (IC 95% : 1,73—2,12).nclusion criteria
ligible studies were cohort studies of patients with RA
iagnosed according to the recommendations available dur-
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Table 1 Main characteristics of the studies reporting on standardized mortality ratio (myocardial infarction and/or stroke).
Study Location,
study period
Patients (n) Age Women (%) Disease
duration at
inclusion
Follow-up (RA
patients)
Completeness
of follow-up
Validation Consecutive
Monson USA,
1930—1960
1035 NA 74 NA Up to 1972 27% lost to
follow-up
DC Yes
Lewis UK,
1966—1976
311 NA NA NA 11 years Complete DC (41%
autopsy)
Yes
Allebeck Sweden, 1971 1165 NA 46 NA Up to 1978 Complete Autopsy (67%)
Medical
records
Yes
Prior England,
1964—1978
489 NA 65 NA 11.2 years 8.4% lost to
follow-up
DC Yes
Erhardt UK, 1979 308 59 71 7.4 years Up to 1985 Complete DC Yes
Reilly England,
1957—1963
100 51 64 3.7months 25 years Adequate Autopsy
(n = 19),
medical
records
< 1 year
duration
Wolfe a USA,
1965—1990Canada,
1966—1974
3501 53 74 NA Canada:
15.8US:
8.5 years
2.5, 4.5 33.6
and 10.5% lost
to follow-up
DC Yes
Wallberg-Jonsson Sweden, 1979 606 55 68 12.5 years 15 years Complete Medical
records and
DC
No,
seropositive
Bjornadal Sweden,
1964—1994
46,917 NA 71 NA 489,048
persons—years
Complete DC Yes
Thomas Scotland,
1981—2000
33,318 61.8 73 NA 6.9 years Complete DC Yes
Goodson England,
1981—1996
1010 60.4 72 Newly
diagnosed
11.4 years 97% DC Newly
diagnosed
Young England,
1986—1997
1429 55 66 6months 9.1 years Complete DC < 2 years’
duration
DC: death certiﬁcates.
a This study included rheumatoid arthritis patients from four centres and at different periods.
2 C. Meune et al.
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ng the study period [11]. Articles had to report either
nough data to compute a SMR or an IRR for at least
ne of the following outcomes: fatal or non-fatal MI,
atal or non-fatal stroke. Studies that reported death
elated to ‘‘ischemic heart disease’’, ‘‘arteriosclerotic
eart disease’’ or ‘‘coronary artery disease’’ were con-
idered as relevant; their results were computed as fatal
I. In cases of multiple publications from the same
ohort, we chose the study that provided the greatest
mount of information (i.e., the largest number of patient-
ears).
tudy selection
wo reviewers independently reviewed the studies to
ssess their eligibility for inclusion in the review. Disagree-
ents were resolved by consensus. The two reviewers
xtracted data from the selected studies separately. Dis-
greements were resolved by consensus among all authors.
o describe population characteristics, we abstracted the
ollowing: geographic area, mean age, female proportion,
nd mean duration of disease. To assess quality criteria,
e abstracted the following: prospective study, consecu-
ive enrolment, population-based study and completeness of
ollow-up.
tatistical analysis
MR and IRR and their 95% conﬁdence intervals (CIs) were
alculated with crude numbers extracted from individual
tudies. Publication bias was assessed graphically, using a
unnel plot [12].
If SMRs were reported without 95% CI, the interval
as calculated using observed and expected number of
eaths and assuming a Poisson distribution of observed
ases. Pooled estimates of SMR for fatal MI and fatal
troke—IRR for MI and stroke—were calculated using the
nverse variance method with the STATA meta-analysis pro-
ram (STATA 10 software, StataCorp L, College Station,
X, USA). According to the heterogeneity test (signiﬁ-
ance at 5% level) either a ﬁxed or a random-effects
odel was applied. To estimate the inﬂuence of individ-
al studies on the summary effect estimate, meta-analysis
stimates were re-computed omitting one study at a
ime.
esults
mong a total of 1939 references identiﬁed, 16 studies
ulﬁlled our inclusion criteria. From abstract books of
onferences we retrieved one abstract that fulﬁlled our
nclusion criteria. Thus, we ultimately selected and included
7 studies, including one abstract, corresponding to a total
opulation of 124,894 patients (Fig. 1). The characteris-
ics of the studies included in the review are given in
able 1 (SMR)Table 2 (IRR). SMRs stratiﬁed by speciﬁc cohort
haracteristics are presented in Table 3 as highest, lowest
nd pooled estimates.
Funnel plots did not show evidence of publication bias
data not shown). T
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Table 3 Pooled estimates of mortality stratiﬁed by cohort characteristics.
No. of
studies
Lowest
SMR
95% CI Highest
SMR
95% CI Pooled
SMR
95% CI
MI All studies 10 0.99 0.71—1.37 3.82 2.22—6.58 1.77 1.65—1.89
Nationality
Scandinavian/Scottish
studies
3 0.99 0.71—1.37 1.83 1.78—1.89 1.77 1.65—1.90
Non-Scandinavian/non-
Scottish
studies
7 1.42 0.88—2.28 3.82 2.22—6.58 1.83 1.54—2.16
Disease duration
0—1 year 3 1.42 0.88—2.28 1.76 1.47—2.09 1.60 1.42—1.80
> 1 year 2 0.99 0.71—1.37 3.82 2.22—6.58 1.42 1.01—1.88
Stroke All studies 9 1.08 0.84—1.39 2.00 1.14—3.52 1.46 1.31—1.63
Nationality
Scandinavian/Scottish
studies
4 1.10 0.72—1.69 1.74 1.67—1.81 1.61 1.45—1.77
Non-Scandinavian/non-
Scottish
studies
5 1.10 0.83—1.46 2.00 1.14—3.52 1.37 1.01—1.72
Disease duration
0—1 year 2 1.10 0.83—1.46 2.00 1.14—3.52 1.24 0.96—1.60
> 1 year 1 — — 1.10 0.72—1.69 —
> 1 year
CI: conﬁdence interval; MI: myocardial infarction; SMR: standardized m
Figure 1. Study ﬂow chart. MI: myocardial infarction; SMR: stan-
dardized mortality ratio; IRR: incidence rate ratio.
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atal and non-fatal myocardial infarction
en studies reported on SMR for fatal MI, corresponding to a
otal of 85,323 patients [13—22] (Table 1). SMR from fatal MI
anged from 0.99 to 3.82. Seven studies demonstrated a sig-
iﬁcant increase in fatal MI [13,14,16,17,19,20,22], whereas
he three remaining did not. Data were pooled by use of the
andom-effects model, as the heterogeneity test was sig-
iﬁcant (2 = 31, P < 0.001). The pooled SMR was 1.77 (95%
I 1.65—1.89) (Fig. 2, Table 3). The omission of one study
rom a subsequent analysis had no signiﬁcant impact on the
eta-analysis estimates.
Three studies included patients from Sweden [18,19] or
cotland [22], regions assumed to be at high risk of car-
iovascular events. Mortality rates were similar in these
tudies conducted in Sweden/Scotland and in those per-
ormed in the USA/England (Table 3). Five studies reported
ean disease duration in their cohort, which was less
han 1 year in three studies [15—17] and greater than
year in the two remaining studies [18,20]. Pooled SMRs
isclosed similar mortality in patients with less than 1-
ear of disease duration than in the remaining patients
Table 3).
Five studies, including one study as yet only published
s an abstract [23], reported on IRR for total MI [4,23—26],
orresponding to a total of 34,705 patients. The pooled esti-
ate of the IRR was 2.10 (1.52—2.89; P < 0.0001) (Fig. 3).
he exclusion of the abstract did not alter the pooled esti-
ate of IRR.
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Figure 2. Forest plot of myocardial infarction standardized mo
epresents an individual SMR estimate, the size of the square bein
onﬁdence interval for the point estimate in each study.
atal and non-fatal stroke
he nine included studies (88,500 patients) reported
MR from fatal stroke ranging from 1.08 to 2.00
13—16,18,19,22,27,28]. Data were pooled by use of the
andom-effects model, as the heterogeneity test was sig-
iﬁcant (2 = 34, P < 0.001). The pooled SMR for stroke was
.46 (95%CI 1.31—1.63) (Fig. 4). The omission of one study in
n alternative analysis had no impact on the meta-analysis
stimates. Four studies reported the risk of stroke among
atients from Scandinavia or Scotland [18,19,22,28]; the
ooled SMR for stroke was similar in these patients from
candinavia/Scotland than in the remaining patients from
he USA/England (Table 3). Only three studies reported
D
O
a
s
igure 3. Incidence rate ratio (IRR) for myocardial infarction in rheumy ratio (SMR) for patients with rheumatoid arthritis. Each square
portional to the weight of the study. The lines represent the 95%
ean disease duration in their cohort, which was less than
year in two studies [15,16] and greater than 1 year in a sin-
le cohort [18]. SMRs for stroke were similar among these
tudies (Table 3).
Lastly, three studies reported on IRR for total stroke
26,143 patients) [4,24,25]. The pooled estimate was 1.91
95%CI 1.73—2.12; P < 0.0001) (Fig. 5).iscussion
ur study is an update of the risk of fatal and non-fatal MI
nd stroke in RA. Its main result is that the risks of MI and
troke are increased in RA patients.
atoid arthritis with 95% conﬁdence intervals and the combined IRR.
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The primary strengths of our study are the inclusion of
recent studies, the application of strict search and inclu-
sion criteria, and the assessment of population-based cohort
studies only. In addition, all included studies reported data
on patients with RA deﬁned according to recommendations
available at the moment of the study.
It has been suggested that the impact of RA on the risk
of stroke may be weaker possibly because of the longer
time to occurrence of cerebrovascular events [10]. Our study
shows that both MI and stroke are more frequent in RA
patients than in the general population, and suggest that
both MI and stroke account for a similar extent in the
observed mortality and CV events observed in RA. Our results
are consistent with both our knowledge of atherosclero-
sis as a systemic disease [29], and the hypotheses that
v
s
d
p
Figure 5. Incidence rate ratio (IRR) for stroke in rheumatoid arthritisr patients with rheumatoid arthritis. Each square represents an
the weight of the study. The lines represent the 95% conﬁdence
ave been generated to explain such an increase in CV
vents in RA patients. Traditional risk factors for atheroscle-
osis should be considered as important contributors to
V events in RA patients [6,30—32]. Indeed, atherogenic
ipid proﬁle may warrant special consideration, as previ-
us studies have demonstrated that RA patients have raised
ow-density lipoprotein, and do have an atherogenic lipid
roﬁle when compared with controls, even before the onset
f articular involvement [33,34]. Inﬂammation by itself may
romote atherosclerotic plaque development, increase their
ulnerability and promote thrombosis [18,35—38]. As a con-
equence, one may expect that all forms of atherosclerotic
isease should be increased in RA.
Age at inclusion and disease duration may be important
arameters to consider when analysing the literature. How-
with 95% conﬁdence intervals and the combined IRR.
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ver, age ranged from 51 to 61.8 years in the studies included
n our analysis, with most patients aged 50—55 years at inclu-
ion. Therefore, we cannot derive any conclusion concerning
he inﬂuence of age in our study. Pooled SMR were similar
n studies that focused on patients with disease duration
ess than 1 year than in studies that reported patients with
ore prolonged disease duration (Table 3). In their study,
unnarsson et al. documented that RA patients were not
eported to have increased MI by the time of the diagnosis
hereas the risk of MI increased signiﬁcantly during follow-
p. This may be interpreted as a progressive risk over time,
ossibly due to prolonged disease, older age or both [23].
e must, however, acknowledge that disease duration may
e hard to ascertain in some patients and was not reported
n many studies.
In our analysis, we did not ﬁnd any association between
he time of the study and both the quality of the studies
i.e., adequate follow-up, validation of events) or the exis-
ence of increased risk of MI or stroke. This is in accordance
ith our previous report that mortality was not signiﬁcantly
ltered during the past 50 years [9]. Such results could be
egarded as in conﬂict with advances in both the man-
gement of RA and cardiovascular disease. In fact, there
s strong evidence that TNF inhibitors may alter the CV
isk of these patients. TNF inhibitors increase high-density
ipoprotein (HDL) cholesterol, may reverse metabolic insulin
esistance, reduce C-reactive protein concentration [10],
nd ultimately reduce the rate of ﬁrst CV events accord-
ng to a longitudinal observational study [39]. However, one
hould keep in mind that SMR is the ratio of observed versus
xpected mortality. Adequate interpretation should be that
I and stroke have decreased in both the general population
nd RA patients with a similar extra risk in RA patients [9].
Our study has some limitations. Our analysis showed het-
rogeneity among study results for MI and stroke. However,
e analysed population-based cohort studies that allowed
he determination of SMR and IRR and used strict inclusion
riterion. In addition, we used a random-effect model to
nclude an estimate of the between-studies variability [40]
nd therefore assume that our results should be considered
s robust. Most of the studies evaluated the prognosis of
atients with disease onset in the 1980 s or early 1990 s,
period when disease-modifying antirheumatic drugs were
oorly prescribed and only minimal attention was paid to
ontrol of inﬂammation and prevention of cardiovascular
vents. Some studies do support the beneﬁcial effect of
hese drugs on mortality; their impact upon MI and stroke
emain to be demonstrated. Lastly, SMR and IRR evaluated
he association between RA and measured outcomes (MI,
troke) adjusted for age and sex and not for traditional risk
actors.
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